A medication long trusted to ease the burden of failing hearts may now offer something to those struggling with a different kind of weight. Spironolactone, a diuretic in use since the late 1950s, has shown in both animal studies and Veterans Affairs patient records that it may meaningfully reduce alcohol cravings and consumption — particularly among the heaviest drinkers. The finding arrives at a moment when only two medications are considered reliably effective for a condition that quietly affects 14.5 million Americans, most of whom never receive any treatment at all. Science, it seems, some
Gizmodo Australia
· Sep 20, 2022
· health
· 3 min read
High
Sourcing: Verified
Heart Drug Shows Promise in Treating Alcohol Use Disorder
Approximately 14.5 million Americans struggle with alcohol use disorder, with less than 10% receiving treatment annually.
◉
Health & Medicine
8046 related articles
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 100% match
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% match
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% match
Related Coverage
Google News · Aug 19
Welsh Teen's Ovarian Cancer Diagnosis Triggers Sudden Menopause
A teenager from Caernarfon experienced sudden onset menopause following an ovarian cancer diagnosis, highlighting unexpe…
JNS.org · Aug 19 Israeli study: Focused attention may reduce inflammatory responseBar-Ilan University researchers found that deliberately focusing attention on inflamed skin areas reduced inflammatory r…
foodsafetynews.com · Aug 19 UK Salmonella outbreak sickens 207, linked to imported eggsA Salmonella outbreak across the UK has infected 207 people with one death, traced to contaminated imported eggs served …
eNCA · Aug 19 DRC Ebola outbreak spreading faster than any previous epidemic, WHO warnsWHO warns the DRC Ebola outbreak is moving faster than any previous epidemic, with over 2,300 deaths from nearly 5,000 c…
Bias & Framing
⚖
Article presents promising research on spironolactone for alcohol use disorder with straightforward reporting, minimal loaded language, though lacks critical perspective on study limitations and competing treatments.
Bias Direction
center
Confidence
MED
Optimistic framing of medical breakthrough using 'second act' metaphor and progressive disclosure of drug's expanding applications, positioning spironolactone as a potential solution to an undertreated condition.
second act
could see a second act
struggling with
few treatments
promising research
Limitations of animal-to-human translation in drug research
Efficacy comparison with existing alcohol use disorder treatments
Potential side effects or contraindications not mentioned
Expert skepticism or cautionary viewpoints from addiction specialists
Cost and accessibility considerations
Long-term efficacy data or duration of treatment effects
Perspectives from people with lived experience of alcohol use disorder
Geopolitical Impact
🌎
Medical research on repurposing spironolactone for alcohol use disorder has no direct geopolitical implications; this is a domestic health policy matter.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Government research suggests spironolactone, an existing heart medication, may reduce alcohol cravings and consumption, potentially creating a new therapeutic market and reducing healthcare costs from alcohol use disorder.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical services
Mental health and addiction treatment
Hospital and clinical services
Patients with alcohol use disorder could access a lower-cost treatment option using an existing, affordable generic medication. This may reduce treatment barriers and improve health outcomes for millions struggling with addiction, potentially decreasing out-of-pocket costs.
FDA may expedite approval pathways for repurposed drugs. Healthcare systems may expand spironolactone prescribing for off-label use. Insurance coverage policies may evolve to include this indication. Public health agencies may increase funding for addiction treatment research and implementation.